DHI1 is an anti-leukemia agent with high selectivity towards Jurkat (IC50= 21.83 µM) and HL-60 (IC50= 19.14 µM) leukemia cells, while exhibiting low toxicity to non-cancerous cells. It induces G2/M cell cycle arrest in both Jurkat and HL-60 leukemia cells and S phase arrest in HL-60 cells, significantly affecting cell cycle signaling molecules such as Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasiveness of Jurkat and HL-60 cells by disrupting the cytoskeletal actin filaments, making it useful for research on hematological malignancies.
Target:
CDK|||Wee1|||Chk
* VAT and and shipping costs not included. Errors and price changes excepted
